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AbstrAct
Aim of the study Probiotic administration to preterm 
infants has the potential to prevent necrotising enterocolitis 
(NEC). Data from randomised controlled trials (RCT) 
are conflicting but meta-analyses seem to support this 
intervention. To date, these analyses have not focused on 
surgical NEC. We aimed to determine the effect of probiotic 
administration to preterm infants on prevention of surgical 
NEC.
Methods A systematic review of RCTs of probiotic 
administration to preterm infants was performed. 
Studies were included if RCT outcomes included any 
of (1) Bell’s stage 3 NEC; (2) surgery for NEC; and (3) 
deaths attributable to NEC. Article selection and data 
extraction were performed independently by two authors; 
conflicts were adjudicated by a third author. Data were 
meta-analysed using Review Manager V.5.3. A random 
effects model was decided on a priori because of the 
heterogeneity of study design; data are risk ratio (RR) with 
95% CI.
Main results Thirty-five RCTs reported NEC as an 
outcome. Seventeen reported surgical NEC; all RCTs were 
included. A variety of probiotic products was administered 
across studies. Description of surgical NEC in most studies 
was poor. Only 6/16 specifically reported incidence of 
surgery for NEC, 12/17 Bell’s stage 3 and 13/17 NEC-
associated mortality. Although there was a trend towards 
probiotic administration reducing stage 3 NEC, this was 
not significant (RR 0.74 (0.52–1.05), p=0.09). There was 
no effect of probiotics on the RR of surgery for NEC (RR 
0.84 (0.56–1.25), p=0.38). Probiotics did, however, reduce 
the risk of NEC-associated mortality (RR 0.56 (0.34–0.93), 
p=0.03).
conclusion Despite 35 RCTs on probiotic prevention of 
NEC, evidence for prevention of surgical NEC is not strong, 
partly due to poor reporting. In studies included in this 
meta-analysis, probiotic administration was associated 
with a reduction in NEC-related mortality.
IntroductIon
Although necrotising enterocolitis (NEC) is 
the most common life-threatening surgical 
emergency affecting neonates, we still do 
not know how to prevent or medically treat 
the disease.1 Many infants with NEC may 
have surgery with the aim of removal of 
necrotic intestine. Although the indications 
for surgery are not well defined, radiolog-
ical evidence for intestinal perforation is 
often regarded as an absolute indication for 
surgery, and many surgeons would operate 
for failure to improve, or clinical deteriora-
tion, in response to medical management 
such as cessation of enteral feeds, antibiotic 
treatment and supportive treatment.2 In 
the last few years, there has been a surge of 
interest in the potential role of probiotics 
to prevent NEC and this has resulted in the 
publication of many randomised controlled 
trials (RCT), followed by systematic 
reviews and meta-analyses of these RCTs.3–6 
Some commentators have asserted that 
it is ‘almost unethical’ to withhold probi-
otic administration to all preterm infants 
in order to prevent NEC.6 As the type/
strain, dose, duration and timing of probi-
otics are not standardised, others find the 
evidence less compelling.7 The American 
Pediatric Surgical Association Outcomes 
and Clinical Trials Committee8 considered 
the level of evidence for routine probiotic 
What this study hopes to add?
 ► The reporting of surgical aspects of NEC in RCTs of 
probiotic administration is poor.
 ► Probiotic administration is associated with a 
decrease in NEC-associated mortality.
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Original article
What is already known on this topic?
 ► In various randomised controlled trials (RCT) and 
meta-analyses, it was suggested that probiotic 
administration is associated with decrease in 
incidence of definite necrotising enterocolitis (NEC).
 ► The evidence that probiotic administration is 
associated with a decreased incidence of surgical 
NEC is limited.
 ► This is due to poor reporting of surgical NEC in 
RCTs and we urge better reporting of surgical 
aspects of NEC in future trials.
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supplementation and concluded that available data 
supported the routine supplementation of premature 
infants with probiotics although no conclusions could 
be drawn for the extremely low birth weight popula-
tion (ie, those with the highest incidence of NEC) due 
to lack of data. However, most RCTs, and the system-
atic reviews and meta-analyses that result, focus on the 
development of confirmed NEC (ie, Bell’s stage 2) and 
not on the potential effect of probiotic administration 
on surgical NEC. We focused on surgical NEC since 
there is general recognition that infants who are treated 
surgically have more advanced disease than those who 
are managed medically and importantly are noted to 
have worse outcomes including higher mortality, more 
frequent need for further surgery and greater long-term 
neurodevelopmental impairment. The aim of this study 
was to perform a systematic review and meta-analysis in 
order to compare the effects of probiotic administra-
tion and placebo on surgical NEC in preterm infants.
Methods
A systematic review of available literature (Ovid 
Medline January 1974–June 2017) was conducted 
using the search strategy (probiotic* OR pro-biotic* or 
probio* OR lactobacill* OR bifidobacter* OR saccha-
romyces* OR bacillus) AND ((necrotizing enterocolitis 
or necrotising enterocolitis or necrotizing entero-colitis 
or necrotising entero-colitis) OR (necrot* and (entero-
coli* or entero-coli*)) OR (‘necrotizing’ or ‘entero-co-
litis’ or ‘enterocolitis’) and NEC) AND publication type 
randomized controlled trial. A similar search was also 
conducted in Ovid Embase (January 1980–June 2017). 
Hand searching of the reference lists of published 
studies and citation searching using Web of Knowledge 
(Thomson-Reuter) were also performed in order to 
identify additional studies. A formal protocol was not 
prepared for this study.
Inclusion criteria were defined as follows: (1) RCT; (2) 
study compared enteral probiotics to placebo or no treat-
ment; (3) study population defined as premature infants; 
(4) explicit data available on incidence of either (A) Bell’s 
stage 3 NEC, (B) surgery for NEC or (C) NEC-associated 
mortality. Initial screening for inclusion was performed 
independently by two authors using the online tool 
Covidence systematic review software (Veritas Health 
Innovation, Melbourne, Australia, available at http://
www. covidence. org). Adjudication regarding inclusion/
exclusion was performed by the other two authors. The 
following data were extracted: number of infants treated 
with probiotic/placebo, infants with/without Bell’s stage 
3 NEC, infants having surgery for NEC (including perito-
neal drain), Bell’s stage 2/3 NEC, deaths attributable to 
NEC. Data on Bell’s stage 2/3 NEC, the outcome measure 
most frequently reported in meta-analyses of probiotics 
for prevention of NEC, were extracted from included 
papers (ie, only those including surgical outcomes) in 
order to determine whether this subset of papers was 
representative of the larger group of studies with broader 
inclusion criteria.
Data were meta-analysed using Review Manager V.5.3. 
A random effects model was decided on a priori because 
of the heterogeneity of study design; data are risk ratio 
(RR) with 95% CI; heterogeneity was assessed using I2 
and associated χ2 test, and funnel plots prepared for 
assessment of bias across studies. An additional analysis 
(not preplanned) using bacterial products only was also 
performed. Power calculations were performed using an 
online tool (Sealed Envelope 2012), power calculator for 
binary outcome superiority trial, available at: https://
www. sealedenvelope. com/ power/ binary- superiority/ 
using an α error of 5% and β of 80%.
results
The search strategy yielded 169 abstracts, and further 
searching an additional abstract that was poten-
tially eligible. Full-text screening as described in the 
Methods section led to the selection of 19 articles for 
inclusion9–27 and 24 articles for exclusion.28–51 A flow 
chart indicating screening, inclusion and exclusion 
of studies is shown in figure 1. Characteristics of the 
19 included studies are shown in table 1. The lack of 
consistency and clarity regarding definition of NEC as 
an RCT outcome, and reporting of surgical NEC (Bell’s 
stage 3, infants having surgery for NEC) were notable. 
Most excluded papers did not report surgical NEC; two 
further papers26 27 were included as it was possible to 
extract data on surgical outcomes from the papers only 
because there was a zero incidence of NEC in either 
arm (and therefore a zero incidence of surgical NEC) 
rather than explicit reporting of surgical NEC in the 
RCT outcomes.
bell’s stage 2/3 nec
Data on Bell’s stage 2/3 NEC were obtainable from 
19/19 included studies9–27; incidence in the placebo 
group varied between 16% and 0%. Probiotic admin-
istration was associated with a significant reduction in 
the incidence of Bell’s stage 2/3 NEC (RR 0.64 (0.48, 
0.84), p<0.002). There was a low degree of heterogeneity 
between studies (I2=14%, p=0.29).
bell’s stage 3 nec
Data on Bell’s stage 3 as an outcome were available from 
14/19 included studies,9–12 14 16–18 21 22 24–27 of which 12/19 
explicitly reported Bell’s stage 39–12 14 16–18 21 22 24 25; inci-
dence in the placebo group varied between 7% and 
0%. Probiotic usage was not associated with a significant 
effect on the incidence of stage 3 NEC, although there 
was a trend towards a decrease, with a similar RR to that 
of Bell’s stage 2–3 NEC (RR 0.74 (0.51–1.05), p=0.09, 
figure 2). There was no evidence for significant hetero-
geneity (I2=0%, p=0.73).
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Figure 1 Flow chart showing selection of studies for inclusion in the systematic review and meta-analysis. NEC, necrotising 
enterocolitis.
surgery for nec
Data on surgery for NEC were available from only 8/19 
studies10 12 13 17 18 22 26 27 of which only 6/19 explicitly 
reported incidence of surgery for NEC.10 12 13 17 18 22 There 
was no effect of probiotics on the RR of surgery for NEC 
(RR 0.84 (0.56–1.25), p=0.38, figure 2). There was no 
evidence for significant heterogeneity (I2=0%, p=0.83).
deaths attributable to nec
Data on death attributable to NEC were available from 
15/19 studies9 11–15 17 19–23 25–27; of these 13/19 explic-
itly reported death attributable to NEC.9 11–15 17 19–23 25 
In one study, some deaths were reported as being from 
Bell’s stage 1; however, by consensus these deaths were 
not included as the diagnosis of NEC had not been 
confirmed.25 Probiotic administration was associated 
with a significant reduction in the risk of NEC-associated 
mortality (figure 2, RR 0.56 (0.34–0.93), p=0.03) with no 
evidence for significant heterogeneity (I2=0%, p=0.85).
Analysis by probiotic product
We repeated the analyses, excluding those using only a 
fungal probiotic product.14 23 26 Administration of bacte-
rial probiotic products was associated with a significant 
reduction in the incidence of Bell’s stage 2/3 NEC (RR 
0.57 (0.41, 0.80), p=0.001), a trend towards a decrease 
in Bell’s stage 3 NEC (RR 0.73 (0.50–1.05), p=0.09), no 
effect on the RR of surgery for NEC (RR 0.84 (0.56–1.25), 
p=0.38) and a significant reduction in the risk of NEC-as-
sociated mortality (RR 0.53 (0.31–0.90), p=0.02).
Assessment of bias
The risk of bias in individual studies is shown in online 
supplementary table 1. In order to assess evidence for 
publication bias, funnel plots for each of the outcomes 
(Bell’s stage 2/3, Bell’s stage 3, surgery for NEC and 
mortality attributable to NEC) were generated (figure 3). 
For each outcome, the apex of the funnel plot is an RR 
of <1, providing some limited evidence for bias towards 
publication of studies favouring probiotic administra-
tion, although the ability to detect publication bias is 
limited by the low number of publications for some of 
these outcomes.
dIscussIon
Over the past 10 years, there have been many meta-anal-
yses and Cochrane Reviews evaluating probiotic admin-
istration for the prevention of NEC.3–6 To our knowl-
edge, none to date has specifically focused on whether 
or not probiotics reduce NEC requiring surgery. In our 
present systematic review, we found that surgical aspects 
of NEC were rather poorly reported in RCTs of probiotic 
administration; of 37 papers reporting any data on NEC 
as an RCT outcome, only 18 (49%) specifically reported 
surgical NEC (and in a further two data could be extrap-
olated due to the zero incidence of any NEC), and in one 
of these, data could not be used due to unconventional 
reporting of Bell’s staging.51
The available data from included papers suggest 
that probiotic administration was not associated with a 
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Figure 2 Meta-analysis of included studies. (A) Bell’s stage 3 NEC (necrotising enterocolitis) in infants who received probiotic 
or placebo. (B) Surgery for NEC in infants who received probiotic or placebo. (C) Mortality attributed to NEC in infants who 
received probiotic or placebo. df, degrees of freedom.
significant decrease in the risk of developing Bell’s stage 
3 NEC or having surgery for this condition. Previous 
meta-analyses of probiotics have shown a significant 
effect of probiotic administration in decreasing the inci-
dence of Bell’s stage 2–3 NEC. In order to determine 
whether the 16 papers that specifically reported surgical 
NEC were representative of the larger group of papers 
that report Bell’s stage 2–3 NEC, we also analysed the 
effect of probiotic administration on Bell’s stage 2–3 NEC 
in the 16 papers reporting surgical NEC. Consistent with 
the findings of other meta-analyses with less restrictive 
inclusion criteria,3–5 52 we also demonstrated a signifi-
cant decrease in the risk of developing Bell’s stage 2–3 
NEC with probiotic administration. Although the risk of 
developing Bell’s stage 3 NEC was similar to that of devel-
oping stage 2–3 NEC, the difference in risk of Bell’s stage 
3 disease was non-significant. This was due to wider CIs 
associated with a smaller number of patients.
This review has demonstrated a statistically signif-
icant effect of probiotics in reducing mortality 
attributed to NEC, with a relative risk of 0.56. It is 
of interest to analyse specifically mortality attribut-
able to NEC as most meta-analyses examine all-cause 
mortality3–5 52 and we are not aware of any that have 
analysed mortality attributable to NEC. It may seem 
counterintuitive that probiotics significantly decrease 
the risk of NEC-associated mortality without a signif-
icant effect on the risk of surgical NEC. This can be 
explained first because more studies reported deaths 
than reported either Bell’s stage 3 or surgery for NEC. 
Second, up to 20% of infants who have been diag-
nosed as having definite NEC die without ever having 
an operation or a postmortem examination,53 and in 
addition, many of the studies reporting mortality from 
NEC did not have mortality as a defined primary or 
secondary endpoint.
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Figure 3 Funnel plots of included studies. (A) Bell’s stage 2–3 NEC in infants who received probiotic or placebo. (B) Bell’s 
stage 3 NEC in infants who received probiotic or placebo. (C) Surgery for NEC in infants who received probiotic or placebo. (D) 
Mortality attributed to NEC in infants who received probiotic or placebo. RR, risk ratio.
There are a number of potentially confounding 
factors that should be considered when interpreting 
these results. None of the RCTs reviewed for this study 
included a protocol for the decision to proceed to 
surgery nor precise indications for surgery in infants 
with NEC. This is an important factor to consider given 
the decision or indication to perform surgery may differ 
between surgeons and centre.2 A further confounding 
issue is the likely inclusion of infants with spontaneous 
intestinal perforation (SIP) in reports of infants with 
NEC. Many surgeons have debated whether SIP and NEC 
are a similar disease but there is now greater acceptance 
that they are distinct disease entities. We are not aware 
of any reports that suggest probiotics influence the risk 
of developing SIP. Although our present study does not 
show evidence that probiotics reduce surgical NEC, we 
acknowledge that in the absence of consistent reporting 
of both indications for surgery and definitions of NEC/
SIP, we should be cautious when generalising our find-
ings. Diagnosis of NEC, staging of the disease according 
to Bell’s criteria, is a problematic area, and both pneu-
matosis intestinalis (the main criterion used to define 
Bell’s stage 2 NEC) and pneumoperitoneum (the main 
criterion used to define Bell’s stage 3 NEC) have poor 
interobserver agreement—even between expert radiol-
ogists.54–56 It is also worth noting that not all probiotic 
RCTs had independent radiologists.
There are many difficulties in meta-analysing probiotic 
trials. Cross colonisation of the placebo group is one, 
with data from one RCT12 suggesting that up to 37% 
of placebo allocated participants were colonised with 
the probiotic intervention after 2 weeks. Inconsistent 
and limited data reporting trial outcomes by colonisa-
tion status precluded such analyses in our present study, 
though data from one large RCT suggest non-signifi-
cant trends towards reduced NEC in babies successfully 
colonised with probiotics. Furthermore, probiotics work 
through a diverse range of mechanistic actions and not 
all probiotics act via the same mechanism.57 One of the 
controversies in using probiotics relates to the uncer-
tainty of which probiotic will achieve optimum benefit. 
In this meta-analysis, a variety of different probiotic prod-
ucts were used. Even if we concluded that probiotics were 
effective in preventing surgical NEC, we would not be 
able to recommend a specific product, strain, concentra-
tion or even species. Too few studies are available to be 
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able to be meaningfully analysed by the type of probiotic 
administered.
Given the observed data, in order to detect a significant 
difference in Bell’s stage 3 NEC, an RCT would need to 
recruit 2757 patients in each arm. This is likely prohibi-
tive, so we may never have robust evidence to answer the 
question of whether probiotic administration prevents 
surgical NEC. However, recent advances in under-
standing the microbiological basis for the development 
of NEC58 provide some hope that appropriately targeted 
probiotic therapies could be effective in reducing the 
devastating effects of this disease. In conducting future 
RCTs we recommend that robust reporting of surgical 
NEC, SIP and any abdominal surgery (eg, indications for 
surgery, operation performed, surgical outcomes) will 
allow us to more clearly assess the benefits of probiotic 
interventions.
Funding SE gratefully acknowledges support from Great Ormond Street Children’s 
Charity and the NIHR Great Ormond Street Biomedical Research Centre. 
disclaimer The funders had no input into the systematic review.
competing interests SE has received consultancy fees from Fresenius-Kabi and 
a speakers honorarium from Danone.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
reFerences
 1. Hall NJ, Eaton S, Pierro A. Necrotizing enterocolitis: prevention, 
treatment, and outcome. J Pediatr Surg 2013;48:2359–67.
 2. Rees CM, Hall NJ, Eaton S, et al. Surgical strategies for necrotising 
enterocolitis: a survey of practice in the United Kingdom. Arch Dis 
Child Fetal Neonatal Ed 2005;90:F152–F155.
 3. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing 
enterocolitis in preterm infants. The Cochrane database of 
systematic reviews 2014;4:CD005496.
 4. Lau CS, Chamberlain RS. Probiotic administration can prevent 
necrotizing enterocolitis in preterm infants: a meta-analysis. J 
Pediatr Surg 2015;50:1405–12.
 5. Wang Q, Dong J, Zhu Y. Probiotic supplement reduces risk of 
necrotizing enterocolitis and mortality in preterm very low-birth-
weight infants: an updated meta-analysis of 20 randomized, 
controlled trials. J Pediatr Surg 2012;47:241–8.
 6. Deshpande G, Rao S, Patole S, et al. Updated meta-analysis 
of probiotics for preventing necrotizing enterocolitis in preterm 
neonates. Pediatrics 2010;125:921–30.
 7. Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review 
of the level of evidence for routine use of probiotics for reduction of 
mortality and prevention of necrotizing enterocolitis and sepsis in 
preterm infants. Clin Nutr 2012;31:6–15.
 8. Downard CD, Renaud E, St Peter SD, et al. Treatment of necrotizing 
enterocolitis: an American Pediatric Surgical Association Outcomes 
and Clinical Trials Committee systematic review. J Pediatr Surg 
2012;47:2111–22.
 9. Fernández-Carrocera LA, Solis-Herrera A, Cabanillas-Ayón M, et 
al. Double-blind, randomised clinical assay to evaluate the efficacy 
of probiotics in preterm newborns weighing less than 1500 g in the 
prevention of necrotising enterocolitis. Arch Dis Child Fetal Neonatal 
Ed 2013;98:F5–F9.
 10. Al-Hosni M, Duenas M, Hawk M, et al. Probiotics-supplemented 
feeding in extremely low-birth-weight infants. J Perinatol 
2012;32:253–9.
 11. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent 
necrotizing enterocolitis in very low birth weight neonates. J Pediatr 
2005;147:192–6.
 12 Costeloe K, Hardy P, Juszczak E, et al. Probiotics in Preterm Infants 
Study Collaborative Group. Bifidobacterium breve BBG-001 in 
very preterm infants: a randomised controlled phase 3 trial. Lancet 
2016;387:649–60.
 13. Dani C, Biadaioli R, Bertini G, et al. Probiotics feeding in prevention 
of urinary tract infection, bacterial sepsis and necrotizing 
enterocolitis in preterm infants. A prospective double-blind study. 
Biol Neonate 2002;82:103–8.
 14. Demirel G, Erdeve O, Celik IH, et al. Saccharomyces boulardii 
for prevention of necrotizing enterocolitis in preterm infants: a 
randomized, controlled study. Acta Paediatr 2013;102:e560–5.
 15. Jacobs SE, Tobin JM, Opie GF, et al. Probiotic effects on late-
onset sepsis in very preterm infants: a randomized controlled trial. 
Pediatrics 2013;132:1055–62.
 16. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence 
and severity of necrotizing enterocolitis in very low birth weight 
infants. Pediatrics 2005;115:1–4.
 17. Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing 
enterocolitis in very low birth weight preterm infants: a multicenter, 
randomized, controlled trial. Pediatrics 2008;122:693–700.
 18. Manzoni P, Mostert M, Leonessa ML, et al. Oral supplementation 
with Lactobacillus casei subspecies rhamnosus prevents enteric 
colonization by Candida species in preterm neonates: a randomized 
study. Clin Infect Dis 2006;42:1735–42.
 19. Oncel MY, Sari FN, Arayici S, et al. Lactobacillus Reuteri for the 
prevention of necrotising enterocolitis in very low birthweight infants: 
a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 
2014;99:F110–5.
 20. Rougé C, Piloquet H, Butel MJ, et al. Oral supplementation 
with probiotics in very-low-birth-weight preterm infants: a 
randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 
2009;89:1828–35.
 21. Saengtawesin V, Tangpolkaiwalsak R, Kanjanapattankul W. Effect 
of oral probiotics supplementation in the prevention of necrotizing 
enterocolitis among very low birth weight preterm infants. J Med 
Assoc Thai 2014;97(Suppl 6):S20–5.
 22. Sari FN, Dizdar EA, Oguz S, et al. Oral probiotics: Lactobacillus 
sporogenes for prevention of necrotizing enterocolitis in very low-
birth weight infants: a randomized, controlled trial. Eur J Clin Nutr 
2011;65:434–9.
 23. Serce O, Benzer D, Gursoy T, et al. Efficacy of Saccharomyces 
boulardii on necrotizing enterocolitis or sepsis in very low birth 
weight infants: a randomised controlled trial. Early Hum Dev 
2013;89:1033–6.
 24. Tewari VV, Dubey SK, Gupta G. Bacillus clausii for prevention of late-
onset sepsis in preterm infants: a randomized controlled trial. J Trop 
Pediatr 2015;61:377–85.
 25. Van Niekerk E, Nel DG, Blaauw R, et al. Probiotics reduce 
necrotizing enterocolitis severity in HIV-exposed premature infants. J 
Trop Pediatr 2015;61:155–64.
 26. Xu L, Wang Y, Wang Y, et al. A double-blinded randomized trial on 
growth and feeding tolerance with Saccharomyces boulardii CNCM 
I-745 in formula-fed preterm infants. J Pediatr 2016;92:296–301.
 27. Totsu S, Yamasaki C, Terahara M, et al. Bifidobacterium and enteral 
feeding in preterm infants: cluster-randomized trial. Pediatr Int 
2014;56:714–9.
 28. Awad H, Mokhtar H, Imam SS, et al. Comparison between killed 
and living probiotic usage versus placebo for the prevention of 
necrotizing enterocolitis and sepsis in neonates. Pak J Biol Sci 
2010;13:253–62.
 29. Braga TD, da Silva GA, de Lira PI, et al. Efficacy of Bifidobacterium 
breve and Lactobacillus casei oral supplementation on necrotizing 
enterocolitis in very-low-birth-weight preterm infants: a double-blind, 
randomized, controlled trial. Am J Clin Nutr 2011;93:81–6.
 30. Chowdhury T, Ali MM, Hossain MM, et al. Efficacy of probiotics 
versus placebo in the prevention of necrotizing enterocolitis in 
preterm very low birth weight infants: a double-blind randomized 
controlled trial. J Coll Physicians Surg Pak 2016;26:770–4.
 31. Costalos C, Skouteri V, Gounaris A, et al. Enteral feeding of 
premature infants with Saccharomyces boulardii. Early Hum Dev 
2003;74:89–96.
 32. Dilli D, Aydin B, Fettah ND, et al. The propre-save study: 
effects of probiotics and prebiotics alone or combined on 
necrotizing enterocolitis in very low birth weight infants. J Pediatr 
2015;166:545–51.
 33. Dutta S, Ray P, Narang A. Comparison of stool colonization in 
premature infants by three dose regimes of a probiotic combination: 
a randomized controlled trial. Am J Perinatol 2015;32:733–40.
group.bmj.com on January 29, 2018 - Published by http://bmjpaedsopen.bmj.com/Downloaded from 
8 Rees CM, et al. BMJ Paediatrics Open 2017;1:e000066. doi:10.1136/bmjpo-2017-000066
Open Access
 34. Kanic Z, Micetic Turk D, Burja S, et al. Influence of a combination of 
probiotics on bacterial infections in very low birthweight newborns. 
Wien Klin Wochenschr 2015;127:210–5.
 35. Hays S, Jacquot A, Gauthier H, et al. Probiotics and growth in 
preterm infants: A randomized controlled trial, PREMAPRO study. 
Clin Nutr 2016;35:802–11.
 36. Hussain M, Jabeen S, Subhani RUH. Role of probiotics in prevention 
of nectrotizing enterocolitis in preterm low birth weight neonates. 
Pak J Med Health Sci 2016;10:455–9.
 37. Kitajima H, Sumida Y, Tanaka R, et al. Early administration of 
Bifidobacterium breve to preterm infants: randomised controlled 
trial. Arch Dis Child Fetal Neonatal Ed 1997;76:F101–7.
 38. Li Y, Shimizu T, Hosaka A, et al. Effects of bifidobacterium breve 
supplementation on intestinal flora of low birth weight infants. 
Pediatr Int 2004;46:509–15.
 39. Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin 
supplementation for prevention of late-onset sepsis in very low-
birth-weight neonates: a randomized trial. JAMA 2009;302:1421–8.
 40. Mihatsch WA, Vossbeck S, Eikmanns B, et al. Effect of 
Bifidobacterium lactis on the incidence of nosocomial infections 
in very-low-birth-weight infants: a randomized controlled trial. 
Neonatology 2010;98:156–63.
 41. Millar MR, Bacon C, Smith SL, et al. Enteral feeding of premature 
infants with Lactobacillus GG. Arch Dis Child 1993;69:483–7.
 42. Mohan R, Koebnick C, Schildt J, et al. Effects of Bifidobacterium 
lactis Bb12 supplementation on intestinal microbiota of preterm 
infants: a double-blind, placebo-controlled, randomized study. J Clin 
Microbiol 2006;44:4025–31.
 43. Nandhini LP, Biswal N, Adhisivam B, et al. Synbiotics for decreasing 
incidence of necrotizing enterocolitis among preterm neonates 
- a randomized controlled trial. J Matern Fetal Neonatal Med 
2016;29:821–5.
 44. Patole S, Keil AD, Chang A, et al. Effect of Bifidobacterium breve 
M-16V supplementation on fecal bifidobacteria in preterm neonates-
-a randomised double blind placebo controlled trial. PLoS One 
2014;9:e89511.
 45. Reuman PD, Duckworth DH, Smith KL, et al. Lack of effect of 
Lactobacillus on gastrointestinal bacterial colonization in premature 
infants. Pediatr Infect Dis 1986;5:663–8.
 46. Rojas MA, Lozano JM, Rojas MX, et al. Prophylactic probiotics to 
prevent death and nosocomial infection in preterm infants. Pediatrics 
2012;130:e1113–20.
 47. Romeo MG, Romeo DM, Trovato L, et al. Role of probiotics in 
the prevention of the enteric colonization by Candida in preterm 
newborns: incidence of late-onset sepsis and neurological outcome. 
J Perinatol 2011;31:63–9.
 48. Roy A, Chaudhuri J, Sarkar D, et al. Role of enteric supplementation 
of probiotics on late-onset sepsis by candida species in preterm 
low birth Weight neonates: a randomized, double blind, placebo-
controlled trial. N Am J Med Sci 2014;6:50–7.
 49. Shadkam MN, Jalalizadeh F, Nasiriani K. Effects of probiotic 
lactobacillus reuteri (DSM 17938) on the incidence of necrotizing 
enterocolitis in very low birth weight premature infants. Iranian 
Journal of Neonatology 2015;6:15–20.
 50. Stratiki Z, Costalos C, Sevastiadou S, et al. The effect of a 
bifidobacter supplemented bovine milk on intestinal permeability of 
preterm infants. Early Hum Dev 2007;83:575–9.
 51. Samanta M, Sarkar M, Ghosh P, et al. Prophylactic probiotics for 
prevention of necrotizing enterocolitis in very low birth weight 
newborns. J Trop Pediatr 2009;55:128–31.
 52. Deshpande G, Rao S, Patole S. Probiotics for prevention of 
necrotising enterocolitis in preterm neonates with very low 
birthweight: a systematic review of randomised controlled trials. 
Lancet 2007;369:1614–20.
 53. Battersby C, Longford N, Mandalia S, et al. Incidence and enteral 
feed antecedents of severe neonatal necrotising enterocolitis 
across neonatal networks in England, 2012-13: a whole-population 
surveillance study. Lancet Gastroenterol Hepatol 2017;2:43–51.
 54. Rehan VK, Seshia MM, Johnston B, et al. Observer variability in 
interpretation of abdominal radiographs of infants with suspected 
necrotizing enterocolitis. Clin Pediatr 1999;38:637–43.
 55. Markiet K, Szymanska-Dubowik A, Janczewska I, et al. Agreement 
and reproducibility of radiological signs in NEC using The 
Duke Abdominal Assessment Scale (DAAS). Pediatr Surg Int 
2017;33:335–40.
 56. Di Napoli A, Di Lallo D, Perucci CA, et al. Inter-observer reliability of 
radiological signs of necrotising enterocolitis in a population of high-
risk newborns. Paediatr Perinat Epidemiol 2004;18:80–7.
 57. Vongbhavit K, Underwood MA. Prevention of Necrotizing 
Enterocolitis Through Manipulation of the Intestinal Microbiota of the 
Premature Infant. Clin Ther 2016;38:716–32.
 58. Warner BB, Deych E, Zhou Y, et al. Gut bacteria dysbiosis and 
necrotising enterocolitis in very low birthweight infants: a prospective 
case-control study. Lancet 2016;387:1928–36.
group.bmj.com on January 29, 2018 - Published by http://bmjpaedsopen.bmj.com/Downloaded from 
and meta-analysis
necrotising enterocolitis: systematic review 
Probiotics for the prevention of surgical
Clare M Rees, Nigel J Hall, Paul Fleming and Simon Eaton
doi: 10.1136/bmjpo-2017-000066
2017 1: BMJ Paediatrics Open: 
 http://bmjpaedsopen.bmj.com/content/1/1/e000066
Updated information and services can be found at: 
These include:
References
 http://bmjpaedsopen.bmj.com/content/1/1/e000066#ref-list-1
This article cites 58 articles, 13 of which you can access for free at: 
Open Access
 http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 29, 2018 - Published by http://bmjpaedsopen.bmj.com/Downloaded from 
